Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") announces that it has extended the expiry date of 5,733,885 outstanding common share purchase warrants (the "November 2024 Warrants") and 133,333 outstanding common share purchase warrants (the "December 2024 Warrants").

The November 2024 Warrants were issued in connection with a non-brokered private placement of subscription receipts and in connection with the RTO transaction (as previously announced on a news release on November 21, 2024).

The December 2024 Warrants were issued in connection with a non-brokered private placement of units of common shares.

The initial exercise price of the November 2024 Warrants and the December 2024 Warrants is $1.00 and remains unchanged.

The November 2024 Warrants had an original expiry date of May 20, 2026. The December 2024 warrants had an original expiry date of June 2, 2026. The Company proposes to extend the expiry date of the November 2024 Warrants and the December 2024 warrants by an additional six months such that the November 2024 Warrants will expire on November 20, 2026, and the December 2024 warrants will expire on December 2, 2026 (the "Extension"). All other terms and conditions of the November 2024 and the December 2024 Warrants will remain unchanged.

The Extension is subject to final approval by the Canadian Securities Exchange (the "CSE"); however, the CSE has granted an exemption from the requirement of Section 6.7(c) (no warrants having been exercised in the last six months) of CSE Policy 6 to permit the Company to undertake the Extension. No action will be required on the part of the holders of the November 2024 and December 2024 Warrants to give effect to the Extension, and replacement warrant certificates will not be issued. Original warrant certificates must be presented to the Company in order to exercise any of the November 2024 and December 2024 Warrants.

On Behalf of the Board of Directors:

Yifftach Biel, Chief Financial Officer
DiagnosTear Technologies Inc.

About DiagnosTear

DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. DiagnosTear's TeaRx™ technology is a diagnostic platform intended for rapid, Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter analysis of non-invasively collected tear fluid. The first CE-IVD, and Israeli MoH-approved test based on the TeaRx™ platform is intended for diagnosis of Dry Eye Syndrome (DES TeaRxTM Dry Eye). This product is not FDA-cleared yet. Beyond DES, DiagnosTear is developing innovative tests based on the TeaRx™ platform for additional ophthalmic indications. Among others, DiagnosTear's pipeline includes TeaRx™ Red Eye: The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis and Allergic conjunctivitis. For additional information about DiagnosTear, please visit https://diagnostear.com.

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295726